Sentence examples for reimbursement recommendations from inspiring English sources

2, 3, 8 We selected drugs for which PBAC, CDR, and NICE had each provided reimbursement recommendations for the same indications between 2007 and 2010.

Table 1 summarizes reimbursement recommendations (and, if applicable, any restrictions) reached by PBAC, CDR, and NICE for the nine drugs/indications evaluated, along with the agency rationale for rejecting any drugs.

5– 7 The objective of this research was to review and compare the oncology-specific reimbursement recommendations that have been made in Canada alongside those made in the United Kingdom by NICE with respect to their recommendations records and the influence of clinical and cost-effectiveness evidence on the recommendations.

One possible additional advantage of greater transparency for the clinical database used in decision-making would be increased discussion and a better understanding of the strength of the evidence for clinical effectiveness for the reimbursement recommendations for different patient subgroups in different countries.

They found variable reimbursement recommendations across the agencies for the three drugs reviewed and speculated as to reasons for differences, including the differences in overall types of clinical and economic evidence considered, although the authors did not describe in detail the evidence considered by each agency in reaching their decisions.

The distribution of clinical uncertainty mirrored the reimbursement recommendation closely, as was demonstrated in the original CDR analysis [ 4].

Since AIFA documentation did not refer to cost-effectiveness per se, the main objective of the schemes was to enable positive reimbursement recommendation on these drugs while ensuring a lower budgetary impact.

The complete set of direct and indirect clinical trials used as the evidence base by the three agencies in informing the drug-reimbursement recommendations was different in most cases, often related to which comparators were considered relevant in each geography.

HTA agencies reached the same recommendation for reimbursement (recommended for listing) for four drugs and different recommendations for five drugs.

The following recommendations recommend action at all levels: Dentistry needs financial resources to expand delivery services, improve Medicaid reimbursement, increase education, and reduce poverty at the societal level.

Other abstracted data included: date of review, funding recommendation, reimbursement criteria, and preferred outcomes (if stated).